| Mind NRG–Minerva Neurosciences: investment, before 202008 acquisition of Mind NRG (CH) by Minerva Neurosciences |
|
| OTHER–Novartis: investment, 201401 acquisition of biologics manufacturing faciltiy in Longmont CO by AveXis |
|
| Hoechst–Clariant: investment, 1997 acquisition of Hoechst Speciality Chemical Business by Clariant |
1997-01-01 |
| KLIFO–PERSON: investment, 2008 acquisition of KLIFO A/S by Alejandra Mørk who joins as CEO |
2008-01-01 |
| China National Nuclear–ITM: radiopharmaceuticals, 2010– collab strategic partnership with CIRC in China |
2010-01-01 |
| FoldRx–Pfizer: investment, 202009– acquisition $53m by Pfizer |
2010-09-01 |
| AVISO GmbH–ALS Automated Lab Solutions: investment, 2011 newly found ALS acquires all assets of AVISO keeping core team intact |
2011-01-01 |
| Boehringer–Minapharm: rec protein production technology, 2011– collab Boehringer early adopter of ProBioGen’s GlymaxX afucosylation technology |
2011-01-01 |
| Meiji Seika Kaisha–Newron: safinamide, 2011– license to develop + manufacture + commercialise safinamide in Asia to Meiji Seika Pharma |
2011-01-01 |
| Rebiotix–SEVERAL: investment, 2011 seed financing round $5m |
2011-01-01 |
| Vivacta–Novartis: investment, 2012 acquisition by Novartis |
2012-01-01 |
| NBE-Therapeutics–OTHER: investment, 201204 start-up funding from a private investor |
2012-04-23 |
| PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch |
2012-12-04 |
| BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery |
2013-01-01 |
| NBE-Therapeutics–Boehringer: investment, 201301 seed financing from BIVF |
2013-01-31 |
| Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund |
2013-11-18 |
| NBE-Therapeutics–Boehringer: investment, 201312 seed financing round extension + final close at total of CHF2.1m incl existing investor BIVF |
2013-12-13 |
| NBE-Therapeutics–OTHER: investment, 201312 seed financing round extension + final close at total of CHF2.1m incl private investors |
2013-12-13 |
| NBE-Therapeutics–SEVERAL: investment, 201312 seed financing round extension + final close at total of CHF2.1m (€1.7m) |
2013-12-13 |
| Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors |
2013-12-19 |
| ArchiMed–SEVERAL: investment, 2014 closing of MED I Fund at €150m |
2014-01-01 |
| Electrochaea–SEVERAL: investment, 2014 financing round Series A |
2014-01-01 |
| Mestex–SEVERAL: investment, 2014 1st financing round |
2014-01-01 |
| Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m |
2014-01-01 |
| Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR |
2014-01-01 |
| Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
| i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg |
2014-08-01 |
| Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € |
2015-01-01 |
| Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF |
2015-01-01 |
| Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) |
2015-01-01 |
| Tricares–CapDecisif: investment, 2015 seed financing round incl investor CapDecisif Management |
2015-01-01 |
| Tricares–Crédit Mutuel-CIC: investment, 2015 seed financing round incl investor CM-CIC Innovation |
2015-01-01 |
| Tricares–GO Capital: investment, 2015 seed financing round incl investor GO Capital |
2015-01-01 |
| Tricares–SEVERAL: investment, 2015 seed financing round with CapDecisif + GO Capital + CM-CIC Innovation |
2015-01-01 |
| OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit |
2015-03-03 |
| Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital |
2015-03-04 |
| Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne |
2015-03-04 |
| Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund |
2015-03-04 |
| Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures |
2015-03-04 |
| Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One |
2015-03-04 |
| AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock |
2015-07-14 |
| Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Labiotech.eu–WestTech Ventures: investment, 201602 seed financing round totalling low €6-digit incl lead investor WestTech Ventures |
2016-02-03 |
| Celonis–SEVERAL: investment, 201606 financing round Series A $27.5m |
2016-06-01 |
| T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors |
2016-11-23 |
| Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II |
2016-12-01 |
| Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares |
2016-12-19 |
| ArchiMed–SEVERAL: investment, 2017 closing of MED II Fund at €315m |
2017-01-01 |
| Cutiss–Univ Zurich: investment, 2017 seed funding from UZH Life Sciences Fund |
2017-01-01 |
| Inveox–SEVERAL: investment, 2017 seed financing round €1m from four business angels |
2017-01-01 |
| Mestex–SEVERAL: investment, 2017 2nd financing round |
2017-01-01 |
| Swixx Biopharma–HBM: investment, 2017 initial investment of HBM Healthcare Investments in Swixx Biopharma AG |
2017-01-01 |
| Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck |
2017-01-12 |
| Axolabs–LGC: investment, 201703 acquisition of Axolabs GmbH by LGC |
2017-03-01 |
| Draupnir Bio–High-Tech Gründerfonds: investment, 201704 seed financing round totalling DKK15m (€2m) inkl investor HTGF |
2017-04-01 |
| Draupnir Bio–SEVERAL: investment, 201704 seed financing round DKK15m (€2m) from Novo Seeds + HTGF |
2017-04-01 |
| Sinopharm–Oncgnostics: molecular diagnostics, 201704– license excl for Gyntect test to CJMT/GeneoDx for China + Hong Kong + Macao |
2017-04-05 |
| Caladrius–Hitachi: investment, 201705 acquisition of PCT LLC by Hitachi Chemical |
2017-05-01 |
| TolerogenixX–Germany (govt): grant, 201705 BMWi Exist Forschungstransfer grant €1.4m |
2017-05-01 |
| Cardior Pharmaceuticals–BioMedPartners: investment, 201705 financing round Series A totalling €15m incl co-lead investor BioMedInvest III Fund |
2017-05-11 |
| Cardior Pharmaceuticals–BMS: investment, 201705 financing round Series A totalling €15m incl co-lead investor BMS |
2017-05-11 |
| Cardior Pharmaceuticals–Boehringer: investment, 201705 financing round Series A totalling €15m incl co-lead investor BIVF |
2017-05-11 |
| Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 201705 financing round Series A totalling €15m incl co-lead investor HTGF |
2017-05-11 |
| Cardior Pharmaceuticals–Life Sciences Partners: investment, 201705 financing round Series A totalling €15m incl co-lead investor LSP |
2017-05-11 |
| Elitech–PAI Partners: investment, 201705– acquisition of Elitech Group by PAI Partners from Ergon Capital Partners |
2017-05-11 |
| Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution |
2017-06-01 |
| Kaken Pharmaceutical–Numab: therapeutic antibody, 201706– collab + license option €na for multispecific antibody for inflammatory disease |
2017-06-13 |
| Hopp Group–CRS Clinical Research Services: investment, 201706 management buy-out of CRS from LTS via holding Apleonex AG |
2017-06-19 |
| Repare Therapeutics–SEVERAL: investment, 201706 financing round Series A $68m co-led by Versant Ventures + MPM Capital |
2017-06-22 |
| GreenLight Biosciences–SEVERAL: investment, 201709 financing round Series D $18m led by Fall Line Capital |
2017-09-13 |
| Labiotech.eu–SEVERAL: investment, 201709 2nd financing round €6-digit led by Wille AG + incl Simon Bungers |
2017-09-18 |
| Labiotech.eu–Wille Finance: investment, 201709 2nd financing round totalling €6-digit incl new + lead investor Wille AG |
2017-09-18 |
| Body Labs–Amazon: investment, 201710 acquisition €na (estimate $50m-$70m) of Body Labs by Amazon |
2017-10-03 |
| SimLeap project–Bicoll: sweetener, 201711–2019 collab Bicoll is project partner |
2017-11-17 |
| SimLeap project–Charité: sweetener, 201711–2019 collab Charité is project partner |
2017-11-17 |
| SimLeap project–Germany (govt): grant, 201711–2019 BMB funding €1.1m out of total project volume of €1.6m |
2017-11-17 |
| SimLeap project–Symrise: sweetener, 201711–2019 collab Symrise is project partner |
2017-11-17 |
| Anaveon–Basel (govt): investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–SEVERAL: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–Univ Zurich: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Institut Virion\Sirion–ExpreS2ion Biotech: expression technology, 201712– collab using ExpreS2 platform for antigen production for IVD tests |
2017-12-04 |
| Roche–DiCE Molecules: small-molecule drug discovery, 201712– multi-year research collab €na using DiCE technology with Genentech |
2017-12-19 |
| Aquila Biolabs–Germany (govt): investment, 2018 financing round pre-Series A totalling 7-digit € incl investor KfW Bankengruppe |
2018-01-01 |
| Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Jürgen Schumacher |
2018-01-01 |
| Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Robert Huber |
2018-01-01 |
| Aquila Biolabs–Seed Fonds Aachen: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Seed Fonds Aachen II |
2018-01-01 |
| Aquila Biolabs–SEVERAL: investment, 2018 financing round pre-Series A 7-digit € from Seed Fonds Aachen II + KfW + J Schumacher + R Huber |
2018-01-01 |
| Century Therapeutics–Fujifilm: iPSC technnology, 2018– collab developm iPSC-derived immune effector cells for cancer + license + supply by FDCI |
2018-01-01 |
| CRISPR Therapeutics–ViaCyte: regenerative medicine, 2018– collab incl gene-edited allogeneic stem cell-derived therapies for type 1 diabetes |
2018-01-01 |
| Dopavision–Germany (govt): grant, 2018– BMBF grant €1.4m over 3 years |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–AstraZeneca: oligonucleotide drugs, 2018– collab AstraZeneca is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Biogen: oligonucleotide drugs, 2018– collab Biogen is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–GSK: oligonucleotide drugs, 2018– collab GSK is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–JnJ: oligonucleotide drugs, 2018– collab Janssen is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Pfizer: oligonucleotide drugs, 2018– collab Pfizer is founding member of EPOC |
2018-01-01 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
